Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 133, Issue 12, Pages 1309-1320
Publisher
Portland Press Ltd.
Online
2019-06-19
DOI
10.1042/cs20190249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
- (2018) Melanie P. Chin et al. AMERICAN JOURNAL OF NEPHROLOGY
- Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non–Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis
- (2018) Kohei Otsubo et al. Clinical Lung Cancer
- Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
- (2018) Bruno Crestani et al. Lancet Respiratory Medicine
- Nintedanib in ovarian cancer
- (2017) Saira Khalique et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The potential role of nintedanib in treating colorectal cancer
- (2017) Antonio Rossi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis
- (2017) Zhenzhen Li et al. NEPHROLOGY
- Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
- (2017) José Antonio Rodríguez-Portal Drugs in research & development
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Novel Anti-fibrotic Therapies
- (2017) Benita L. McVicker et al. Frontiers in Pharmacology
- Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
- (2017) Jonathon Shaw et al. Journal of Thoracic Disease
- GW0742, a High Affinity PPAR-β/δ Agonist Reduces Lung Inflammation Induced by Bleomycin Instillation in Mice
- (2017) M. Galuppo et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model
- (2017) Büsra Öztürk Akcora et al. Scientific Reports
- Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
- (2016) Ulrich Costabel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Novel Mechanisms for the Antifibrotic Action of Nintedanib
- (2016) Sunad Rangarajan et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench
- (2016) Wei-Ting Chang et al. Cardiovascular Diabetology
- Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice
- (2016) J. Zhang et al. CLINICAL SCIENCE
- Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis - a clinical study
- (2016) Ardra Anuradha et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis
- (2016) Yanli Yan et al. KIDNEY INTERNATIONAL
- Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts
- (2016) Sita Virakul et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
- (2016) Francesco Bonella et al. RESPIRATION
- Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
- (2016) Luca Richeldi et al. RESPIRATORY MEDICINE
- Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
- (2016) Martin Kolb et al. THORAX
- New targets in idiopathic pulmonary fibrosis: from inflammation and immunity to remodeling and repair
- (2016) Antoine Froidure et al. Expert Opinion on Orphan Drugs
- Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
- (2015) Jingang Huang et al. ANNALS OF THE RHEUMATIC DISEASES
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
- (2015) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Liver sinusoidal endothelial cells in hepatic fibrosis
- (2015) Laurie D. DeLeve HEPATOLOGY
- Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease
- (2015) Sahar Mohamed El-Haggar et al. Hepatology International
- Defining, Treating, and Understanding Chronic Kidney Disease-A Complex Disorder
- (2015) Dean Campbell et al. Journal of Clinical Hypertension
- Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye
- (2015) Viet Anh Nguyen Huu et al. JOURNAL OF CONTROLLED RELEASE
- Nintedanib: From Discovery to the Clinic
- (2015) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- The role of TIMPs in regulation of extracellular matrix proteolysis
- (2015) Valerie Arpino et al. MATRIX BIOLOGY
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling
- (2014) Xiwu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease
- (2014) Ping-Min Chen et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Association of peroxisome proliferator-activated receptorγ gene Pro12Ala and C161T polymorphisms with cardiovascular risk factors in maintenance hemodialysis patients
- (2014) Feng Liu et al. MOLECULAR BIOLOGY REPORTS
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Antifibrosis Effects of Peroxisome Proliferator-Activated Receptorδon Rat Corneal Wound Healing after Excimer Laser Keratectomy
- (2014) Yun Gu et al. PPAR Research
- Combination therapy: the future of management for idiopathic pulmonary fibrosis?
- (2014) Wim A Wuyts et al. Lancet Respiratory Medicine
- The PPARβ/δ Agonist GW501516 Attenuates Peritonitis in Peritoneal Fibrosis via Inhibition of TAK1–NFκB Pathway in Rats
- (2013) Xuesong Su et al. INFLAMMATION
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peroxisome Proliferator-Activated Receptor δ Agonist, HPP593, Prevents Renal Necrosis under Chronic Ischemia
- (2013) Larisa V. Fedorova et al. PLoS One
- Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial
- (2012) Marian Goicoechea et al. JOURNAL OF NEPHROLOGY
- Protection from liver fibrosis by a peroxisome proliferator-activated receptor agonist
- (2012) K. Iwaisako et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pirfenidone for Diabetic Nephropathy
- (2011) K. Sharma et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
- (2011) Pablo E. Pergola et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrin–TGF-β crosstalk in fibrosis, cancer and wound healing
- (2010) Coert Margadant et al. EMBO REPORTS
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages: Master Regulators of Inflammation and Fibrosis
- (2010) Thomas Wynn et al. SEMINARS IN LIVER DISEASE
- Effect of Pentoxifylline on GFR Decline in CKD: A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial
- (2009) Robert M. Perkins et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis
- (2009) Nicole Reich et al. ARTHRITIS AND RHEUMATISM
- Pirfenidone in idiopathic pulmonary fibrosis
- (2009) H. Taniguchi et al. EUROPEAN RESPIRATORY JOURNAL
- Pirfenidone Is Renoprotective in Diabetic Kidney Disease
- (2009) S. P. RamachandraRao et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Scleroderma
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Mechanisms of Hepatic Fibrogenesis
- (2008) Scott L. Friedman GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started